Essure Implant Litigation
On December 21, 2016, Wexler Wallace Partner Ed Wallace was appointed to the Plaintiffs’ Executive Committee for the coordinated Essure litigation in California against Bayer Corp. The FDA approved Essure as a means of permanent contraception for women on November 4th, 2002 . Although originally designed and manufactured by Conceptus, Essure has since been acquired by the pharmaceutical giant, Bayer Corporation. Since 2002, it is estimated that more than 750,000 women have undergone surgery to implant the Essure device, which until recently had been hailed as the next generation of permanent birth control. Although the device is regarded as a “permanent” implant, it is also considered to be reversible, theoretically offering more flexibility than the alternative tubal ligation surgery.Read more.
Transvaginal Surgical Mesh
On October 20, 2008, the FDA issued a Public Health Notification to health care practitioners, alerting them to serious complications associated with the placement of transvaginal surgical mesh used to treat Pelvic Organ Prolapse (“POP”) and Stress Urinary Incontinence (“SUI”). Wexler Wallace represents a number of women who were injured by this surgical mesh, and is seeking to recover damages on their behalf. Read more.
Invokana Mass Tort Litigation
In 2013, Johnson & Johnson introduced the diabetes drug Invokana to the market. A little more than two years after Invokana’s introduction to the market, the U.S. Food and Drug Administration issued a warning about serious risks associated with Invokana and other similar SGLT2 inhibitors. Problems associated with Invokana include kidney failure, kidney impairment, kidney stones, urinary tract infections, and abnormal weight loss. Wexler Wallace is currently representing individuals who are or have taken Invokana and experienced complications or side effects from taking the drug. Read more.
In re Testosterone Replacement Therapy Products Liability Litigation
Wexler Wallace LLP represents men who have suffered serious side effects arising from the use of testosterone products. On January 1, 2014, the FDA issued an alert and announced that they were investigating the risk of stroke, heart attack, and death in men taking FDA-approved testosterone products. The FDA was reacting to recent studies that suggested that certain groups of men face a considerable risk of heart attacks if they take testosterone. Testosterone products are approved to treat men who lack testosterone or have low testosterone levels, in conjunction with an associated medical condition. Read more.
In re Kugel Mesh Hernia Patch Products Liability Litigation
In December of 2005, at the direction of the FDA, C.R. Bard and Davol announced a recall on the large and extra large varieties of their surgically implanted hernia repair patches, known as the Composix Kugel Mesh Patch. Despite having knowledge of the defective design and manufacture of these patches, C.R. Bard and Davol failed to alert physicians about the potential problems and roughly 75,000 of the patches were sold. Wexler Wallace represents individuals who have had defective Composix Kugel Mesh hernia repair patches implanted in their bodies. Read more.
Xarelto Mass Tort Litigation
Xarelto, one of a new class of anticoagulants (blood thinners), has been linked to a large number of injuries requiring hospitalizations with some resulting in deaths. Like all blood thinners, Xarelto can cause serious internal bleeding in some. Xarelto bleeding is difficult to stop, as there is currently no known reversal agent for this occurrence, therefore hemorrhaging will continue until the drug is cleared from the system. Wexler Wallace LLP is providing case evaluations for individuals who may have been injured while taking Xarelto. Read more.
Paxil, which is manufactured by GlaxoSmithKline PC, is in a class of antidepressants known as Selective Serotonin Reuptake Inhibitors (SSRIs). Women who are taking or took the antidepressant Paxil during pregnancy are at a high risk of their children developing certain birth defects. Read more.
In re Guidant Defibrillators Products Liability Litigation
Wexler Wallace represented numerous personal injury claimants as well as third party payors (which include union health and welfare benefit plans) in this multi-district litigation to recover damages as a result of the nationwide recall of Guidant’s implantable cardiovertable defibrillators (“ICDs”) and cardio resynchronization therapy defibrillators (“CRT-Ds”). After significant litigation, Guidant resolved the cases in the MDL for $195 million. Read more.
In re Medtronic, Inc. Implantable Defibrillators Products Liability Litigation
Wexler Wallace filed suit and served on the Plaintiffs’ Steering Committee in this case brought on behalf of third party payors and personal injury claimants incurring damages associated with Medtronic’s defective defibrillators. Patients who suffered arrhythmias or were at high risk for developing arrhythmias were required to have the defective implantable cardiovertable defibrillators (“ICDs”) and cardio resynchronization therapy defibrillators (“CRT-Ds”) removed and have replacement ICDs and CRT-Ds implanted, at great expense to themselves and to third party payors. Read more.
Hip Implants – DePuy ASR™ Hip System Recall Litigation
On August 26, 2010, DePuy Orthopedics, Inc., a division of Johnson & Johnson, announced a worldwide recall of two hip implant systems – the ASR™ XL Acetabular System and the ASR Hip Resurfacing System. DePuy has estimated that 93,000 total devices have been implanted worldwide. If they have not already experienced hip failure, patients with these implants may now need to undergo costly and painful revision surgery. Read more.